The latest price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $10.00 expecting AUPH to rise to within 12 months (a possible 39.86% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Aurinia Pharmaceuticals (NASDAQ:AUPH) was provided by Cantor Fitzgerald, and Aurinia Pharmaceuticals reiterated their overweight rating.

The last upgrade for Aurinia Pharmaceuticals Inc happened on December 10, 2021 when Oppenheimer raised their price target to $31. Oppenheimer previously had a perform for Aurinia Pharmaceuticals Inc.

The last downgrade for Aurinia Pharmaceuticals Inc happened on November 4, 2022 when Oppenheimer changed their price target from N/A to N/A for Aurinia Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aurinia Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aurinia Pharmaceuticals was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Aurinia Pharmaceuticals (AUPH) rating was a reiterated with a price target of $10.00 to $10.00. The current price Aurinia Pharmaceuticals (AUPH) is trading at is $7.15, which is out of the analyst’s predicted range.